IDEAYA Biosciences, Inc. (IDYA) FY2025 10-K Annual Report
IDEAYA Biosciences, Inc. (IDYA) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 17, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
IDEAYA Biosciences, Inc. FY2025 10-K Analysis
Business Overview
- • Core oncology precision medicine with focus on synthetic lethality and antibody-drug conjugates (ADCs) targeting molecularly defined solid tumors
- • New Phase 3 neoadjuvant trial for darovasertib in primary uveal melanoma initiated, targeting eye preservation and vision improvement
- • Servier exclusive license granted for darovasertib outside U.S., upfront payment $210M plus milestones up to $320M and royalties
- • IDE849 DLL3 TOP1 ADC Phase 1 data in 100 patients shows 48% Grade 3+ TRAEs, median PFS 6.7 months, 83.3% ORR in brain metastasis at 2.4 mg/kg dose
- • GSK terminating collaboration on Pol Theta inhibitor (IDE705) and WRN inhibitor (IDE275), programs transferring back for internal development
Management Discussion & Analysis
- • Collaboration revenue $218.7M in 2025 vs $7.0M in 2024, up 3,024% driven by Servier License Agreement
- • Net loss $113.7M in 2025 vs $274.5M in 2024; loss decreased 59%, operating expenses up 13% to $378.0M
- • Research and development expenses $314.7M (+7%), general and administrative expenses $63.3M (+61%) in 2025
- • Best performing segment: Collaboration revenue surge from Servier deal; worst: continued high R&D expenses, $98.1M on darovasertib
- • Cash, cash equivalents, marketable securities $1.05B as of Dec 31, 2025; raised net $25M from equity ATM offering in 2025
- • Outlook: Cash runway sufficient for 12+ months; expecting higher R&D expenses for clinical advancement; risk of funding shortfall if capital not raised
Risk Factors
- • Regulatory risk: Servier License Agreement contract assets increased $6.0M, indicating dependency on this agreement's terms and regulatory compliance timing
- • Macroeconomic threat: Operating cash used $71.1M in 2025 and $247.6M in 2024, showing high cash burn amid volatile financing environment
- • Operational vulnerability: $10.4M accrued liabilities for CROs, CMOs, consultants, indicating heavy reliance on external research and manufacturing partners
- • Market disruption risk: Not disclosed in text, next material risk is financial
- • Financial risk: Net loss $113.7M in 2025 with $46.1M stock-based compensation, signaling significant operating losses and dilution risk
IDEAYA Biosciences, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$219M
▲ +3024.4% YoY
Net Income
-$114M
▲ +58.6% YoY
Operating Margin
-72.8%
▲ +459823bp YoY
Net Margin
-52.0%
▲ +386911bp YoY
ROE
-11.1%
▲ +1480bp YoY
Total Assets
$1.1B
▼ -1.3% YoY
EPS (Diluted)
$-1.28
▲ +61.9% YoY
Operating Cash Flow
-$71M
▲ +71.3% YoY
Source: XBRL data from IDEAYA Biosciences, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on IDEAYA Biosciences, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.